Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy
Authors
Keywords
Colorectal cancer, <em class=EmphasisTypeItalic >MTHFR</em>, Polymorphisms, Overall survival, 5-Fluorouracil
Journal
International Journal of Clinical Oncology
Volume 22, Issue 3, Pages 484-493
Publisher
Springer Nature
Online
2017-01-02
DOI
10.1007/s10147-016-1080-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer
- (2015) Nai-Chun Wu et al. ANTI-CANCER DRUGS
- Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
- (2015) M. Joerger et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)
- (2014) Cornelia M. Ulrich et al. CANCER
- MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
- (2014) E Cecchin et al. PHARMACOGENOMICS JOURNAL
- MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland
- (2014) Amit A. Negandhi et al. PLoS One
- Associations Between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and Survival of Colorectal Cancer (CRC) Patients Treated with 5-Fluorouracil-Based Chemotherapy
- (2013) Ching-Yu Lai et al. ANNALS OF SURGICAL ONCOLOGY
- Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability
- (2013) Luciano Delgado-Plasencia et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer
- (2013) Jing Zhao et al. MEDICAL ONCOLOGY
- MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer
- (2013) Lieke H. van Huis-Tanja et al. Pharmacogenetics and Genomics
- Tumor Site- and Stage-Specific Associations between Allelic Variants of Glutathione S-Transferase and DNA-Repair Genes and Overall Survival in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy
- (2013) Ching-Yu Lai et al. PLoS One
- Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer
- (2011) F Thomas et al. BRITISH JOURNAL OF CANCER
- Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan
- (2011) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab
- (2011) Barna Budai et al. Pharmacogenetics and Genomics
- Methylenetetrahydrofolate Reductase Polymorphism (677 C>T) Predicts Long Time to Progression in Metastatic Colon Cancer Treated with 5-Fluorouracil and Folinic Acid
- (2010) Omar Castillo-Fernández et al. ARCHIVES OF MEDICAL RESEARCH
- 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes
- (2010) Barbara Pardini et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
- (2010) Ming-Yii Huang et al. Pharmacogenetics and Genomics
- MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
- (2009) S. Afzal et al. ANNALS OF ONCOLOGY
- Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
- (2009) M Gusella et al. BRITISH JOURNAL OF CANCER
- Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients
- (2009) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation
- (2009) Elena De Mattia et al. EUROPEAN JOURNAL OF CANCER
- Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy
- (2009) Antonia M. Fernández-Peralta et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- ERCC22251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study
- (2008) Ming-Yii Huang et al. BMC CANCER
- Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients
- (2008) R. Sharma et al. CLINICAL CANCER RESEARCH
- Methylenetetrahydrofolate Reductase Gene Polymorphisms: Genomic Predictors of Clinical Response to Fluoropyrimidine-Based Chemotherapy in Females
- (2008) Laia Paré et al. JOURNAL OF CLINICAL ONCOLOGY
- Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
- (2008) Georg Lurje et al. Pharmacogenetics and Genomics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now